Article
Food Science & Technology
Jinkyung Lee, Chan Ho Jang, Yoonsu Kim, Jisun Oh, Jong-Sang Kim
Summary: This study examined the ability of quercetin to sensitize colorectal cancer cells to oxaliplatin by inhibiting glutathione reductase activity. The combination of quercetin and oxaliplatin was found to synergistically inhibit glutathione reductase activity, reduce cell viability, and increase reactive oxygen species production. Addition of sulforaphane further enhanced the anti-cancer efficacy of this combination therapy in a mouse model.
Article
Oncology
Mathieu Chocry, Ludovic Leloup, Fabrice Parat, Melissa Messe, Alessandra Pagano, Herve Kovacic
Summary: This study provides insights into the mechanisms of chemoresistance in oxaliplatin-resistant cancer cells and identifies gemcitabine as a potential therapeutic option by inhibiting the Akt and p38 MAPK pathways to induce apoptosis.
Review
Engineering, Biomedical
Rui Sang, Bradley Stratton, Alexander Engel, Wei Deng
Summary: Conventional treatments for colorectal cancer severely impact advanced patients' therapeutic effects. The development of nanomedicines has led to liposomal delivery systems being considered promising for CRC treatment. Recent reviews have focused on preclinical research and drug delivery, but our review provides the latest advances in liposome technology for CRC with strong potential for clinical translation.
ACTA BIOMATERIALIA
(2021)
Review
Pharmacology & Pharmacy
Fang Cheng, Ruoqi Zhang, Chen Sun, Qian Ran, Cuihan Zhang, Changhong Shen, Ziqing Yao, Miao Wang, Lin Song, Cheng Peng
Summary: Oxaliplatin-based chemotherapy is a standard treatment for colorectal cancer but can cause severe peripheral neurotoxicity. This article explores the mechanisms, therapeutic strategies, and pharmacokinetics of different methods of oxaliplatin administration to counteract this toxicity. Strategies include combination with chemoprotectants, timing modulation of infusion, dose reduction, reintroduction of oxaliplatin, and topical administration.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chengzhi Huang, Minjia Wang, Junjiang Wang, Deqing Wu, Yuan Gao, Kaihong Huang, Xueqing Yao
Summary: The study revealed that overexpression of MGP in colorectal cancer may contribute to oxaliplatin resistance and be associated with cancer stage and patient prognosis. Inhibition of MGP expression can increase sensitivity of CRC cells to OXA, potentially reversing resistance and reducing tumor growth.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Li Song, Yu Hao, Chunjie Wang, Yikai Han, Yujie Zhu, Liangzhu Feng, Liyan Miao, Zhuang Liu
Summary: A liposomal nanomedicine that modulates the tumor microenvironment has been developed to enhance cancer immunotherapy. By encapsulating metformin and an oxaliplatin prodrug in liposomes, this nanomedicine reduces tumor hypoxia and induces immunogenic cell death, effectively suppressing tumor growth and reversing immunosuppression.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Oncology
Masanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, Kana Kishimoto, Honoka Takefuji, Yuzuki Taniwaki, Misa Ueda, Tadafumi Hoshida, Kazufumi Tanabe, Shozo Nishida
Summary: This study demonstrated that combined administration of statins and L-OHP effectively induced apoptosis and increased the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP. Additionally, statins regulated the expression of multiple related proteins at the cellular level, enhancing the antitumor effect of L-OHP. Furthermore, statins alleviated L-OHP-induced neuropathy through the activation of ERK1/2 in vivo.
CANCER CELL INTERNATIONAL
(2023)
Article
Cell Biology
Sha Zhou, Jianhong Peng, Liuniu Xiao, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Mengzhong Liu, Zhizhong Pan, Zhenlin Hou
Summary: TRIM25 is identified as an epigenetic regulator of oxaliplatin resistance in colorectal cancer patients, affecting disease-free survival and recurrence rates. Its overexpression promotes stem cell properties in CRC cells and resistance to chemotherapy. Targeting TRIM25 may be a potential strategy for managing OXA resistance in clinical practice.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Yaru Li, Ziru Sun, Yujun Cui, Heming Zhang, Shunjie Zhang, Xinyu Wang, Shengnan Liu, Qingzhi Gao
Summary: Oxaliplatin-based chemotherapy is the current standard of care in advanced colorectal cancer, but acquired resistance limits its efficacy. In response, researchers have designed and synthesized a novel Pt(II) complex, Ph-glu-Oxa, which shows promising in vivo therapeutic potential by targeting DNA and overcoming drug resistance mechanisms.
BIOORGANIC CHEMISTRY
(2021)
Article
Medicine, Research & Experimental
Elham Fakhr, Fatemeh Zare, Kayhan Azadmanesh, Ladan Teimoori-Toolabi
Summary: LEF1 plays an important role in the chemo-resistance of colorectal cancer cells, with downregulation of the long isoform making cells more sensitive to chemotherapy through reduced proliferation, increased apoptosis, or cell cycle arrest. Balancing the expression of long and short isoforms of LEF1 is crucial in overcoming chemo-resistance.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Vera Skripova, Ramilia Vlasenkova, Yan Zhou, Igor Astsaturov, Ramziya Kiyamova
Summary: Chemoresistance is a pressing issue in the field of oncology, especially in pancreatic cancer. This study used CRISPR/Cas9 screening to identify 173 potential regulators of chemotherapy sensitivity in pancreatic cancer cells. Further investigation and validation of these findings will help identify novel platinum sensitivity regulators in pancreatic cancer.
Article
Pharmacology & Pharmacy
Xiaoying Zhang, Wenjing Tang, Haoyu Wen, Ercan Wu, Tianhao Ding, Jie Gu, Zhongwei Lv, Changyou Zhan
Summary: In this study, CTB protein was successfully conjugated with PEGylated liposomes to form CTB-sLip nanocarriers. The CTB-sLip demonstrated high targeting capability to human-derived colorectal cancer cells and lung metastasis in nude mice models. However, repeated injections of CTB-sLip induced the production of antibodies, but it still showed potential for the diagnosis of lung metastasis of colorectal cancer.
Article
Biochemistry & Molecular Biology
Sun Young Park, Ye Seo Chung, So Yeon Park, So Hee Kim
Summary: Resistance to oxaliplatin in colorectal cancer cells is associated with increased phosphorylation of AMPK, leading to cell survival. Inhibition of AMPK can induce autophagy and restore chemosensitivity to anticancer drugs.
Article
Pharmacology & Pharmacy
Jinwei Zhu, Yicui Zhang, Yixin Zhao, Jingwei Zhang, Kun Hao, Hua He
Summary: Despite limited methods for translating organoid-based study results to clinical response, this study developed a PK/PD model using oxaliplatin and irinotecan treatments with colorectal cancer as examples. The model can predict PK profiles and responses following treatments, and may aid in decision-making in drug development and clinical trial design.
Article
Medicine, Research & Experimental
Rong Wang, Jingkun Qu, Xueping Tang, Jiaxin Zhang, Ante Ou, Qianqian Li, Guihua Chen, Caihong Zheng, Bahtiyor Muhitdinov, Yongzhuo Huang
Summary: A lactoferrin-modified gambogic acid liposomal delivery system was developed to enhance the treatment efficacy of colorectal cancer by improving tumor delivery and drug solubility.
MOLECULAR PHARMACEUTICS
(2023)